Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles

Pharmazie

Volumn 64, Issue 2, 2009, Pages 86-89

  Li, Yang ^a   Yehui, Geng ^a   Hao, Li ^a   Yu, Zhang ^a   Jinsong, You ^a   Yanyan, Chang ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; GLYCEROL BEHENATE; PRAZIQUANTEL; SOLID LIPID NANOPARTICLE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG RELEASE; DRUG SYNTHESIS; IN VITRO STUDY; INTESTINE ABSORPTION; MALE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE DRUG DOSE; TRANSMISSION ELECTRON MICROSCOPY; ULTRASOUND; ZETA POTENTIAL;

EID: 74749088620     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2009.8140     Document Type: Article

References (18)

1. Bargoni A, Cavalli R, Caputo O, Fundarò A, Gasco MR, Zara GP (1998) Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm Res 15: 745-750.
2. Becket G, Schep LJ, Tan MY (1999) Improvement of the in vitro dissolution of praziquantel by complexation with α-, β- and γ- cyclodextrins. Int J Pharm 17: 965-971.
3. Castro N, Jung H., Medina R, Gonzalez-Esquivel D, Lopez M, Sotelo J (2002) Interaction between grapefruit juice and praziquantel in humans. Antimicrob Agents Chemother 46: 1614-1616.
4. Castro N, Medina R, Sotelo J, Jung H (2000) Bioavailability of praziquantel increases with concomitant administration of food. Antimicrob Agents Chemoter 44: 2903-2904.
5. Dayan AD (2003) Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics Acta Trop 86: 141-159.
6. Desai MP, Labhasetwar V, Amidon G, and RJ Levy (1996) Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 13: 1838-1845.
7. El-Arini SK, Leuenberg H (1998) Dissolution proprieties of praziquantel-PVP systems. Pharm Acta Helv 73: 89-94.
8. Florence AT, Hillery AM, Hussain N and Jani PU (1995) Nanoparticles as carriers for oral peptide absorption: studies on particles uptake and fate. J Control Rel 36: 39-46.
9. Hanpitakpong W, Banmairuroi V, Kamanikom B (2004) A high-performance liquid chromatographic method for determination of praziquantel in plasma. J Pharmaceut Biomed 36: 871-876.
10. Hu LD, Tang X, Cui FD (2004) Solid lipid nanoparticles to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol 56: 1527-1535.
11. Humberstone J, Charman WN (1997) Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev 25: 103-128.
12. Lavelle EC, Sharf S, Thomas NW, Holland J, Davis SS (1995) The importance of gastrointestinal uptake of particles in the design of oral delivery systems. Adv Drug Deliv Rev 18: 5-22.
13. Jung H, Medina R, Castro N, Corona T, Sotelo J (1997) Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen. Antimicrob Agents Chemother 41: 1256-1259.
14. Mainardes RM, Evangelista RC (2005) PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm 290: 137-144.
15. Mehnert W, Mader K (2001) Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev 47: 165-196.
16. Mourão SC, Costa PI, Salgado HRN and Gremião MPD (2005) Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes. Int J Pharm 295: 157-162.
17. Schwarz C, Mehnert W (1999) Solid lipid nanoparticles (SLN) for controlled drug delivery. Drug incorporation and physicochemical characterization. J Microencapsul 16: 205-213.
18. Yang S, Zhu J, Lu Y, Liang B, Yang C (1999) Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 16: 751-757.